- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03301896
Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
A Phase I/Ib, Open-label, Multi-center Dose-escalation and Dose-expansion Study of the Safety and Tolerability of Intra-tumorally Administered LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
The purpose of this trial was to explore the clinical utility of two investigational agents in patients with advanced cancer.
This was a multi-center, open-label Phase I/Ib study. The primary objectives of the trial were:
- To characterize the safety and tolerability of intratumoral LHC165 in patients with solid tumors as a single agent and in combination with PDR001
- To determine and evaluate the maximum tolerated dose (MTD)/recommended dose (RD) for LHC165 as a single agent and in combination with PDR001
Study Overview
Detailed Description
This was a multi-center, open-label Phase I/Ib study. The study consisted of four dose escalation parts and two dose expansion parts testing LHC165 as a single agent or LHC165 in combination with PDR001. The dose escalation parts estimated the Maximum Tolerated Dose (MTD) and/or Recommended Dose for Expansion (RDE) and were planned to test two different dosing schedules for LHC165 single agent (Group A and B) and LHC165 in combination with PDR001 (Group C and D).
The dose expansion parts of the study were planned to use the MTD/RDE for each the LHC165 single agent (Group E) and LHC165 in combination with PDR001 (Group F), determined in the respective dose escalation parts to assess the activity, safety and tolerability of LHC165 as a single agent or LHC165 in combination with PDR001 in patients with specific types of solid tumors.
The study was terminated due to business reasons. Groups B, D and E were not opened for enrollment.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Wilrijk, Belgium, 2610
- Novartis Investigative Site
-
-
-
-
-
Ulm, Germany, 89081
- Novartis Investigative Site
-
-
-
-
MI
-
Milano, MI, Italy, 20141
- Novartis Investigative Site
-
-
-
-
Tokyo
-
Chuo ku, Tokyo, Japan, 104 0045
- Novartis Investigative Site
-
-
-
-
-
Seoul, Korea, Republic of, 03080
- Novartis Investigative Site
-
-
-
-
-
Madrid, Spain, 28009
- Novartis Investigative Site
-
-
Catalunya
-
Barcelona, Catalunya, Spain, 08035
- Novartis Investigative Site
-
-
-
-
California
-
Los Angeles, California, United States, 90095
- UCLA
-
-
Texas
-
Houston, Texas, United States, 77030
- MD Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent must be obtained prior to any procedures unless considered standard of care.
- Adult men and women (≥ 18 years of age) with histologically confirmed diagnosis of metastatic and/or advanced solid tumors not amenable to curative treatment by surgery.
- Patients must be willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
- Dose escalation: Patients with accessible tumors and with measurable disease as determined by RECIST 1.1 and have progressed despite standard treatment or are intolerant of standard treatment, or for whom no standard treatment exists.
- Dose expansion: Patients with advanced/metastatic solid tumors: HNSCC, melanoma, accessible tumors and visceral tumors (LHC165 combination with PDR001 only). Patients must have measurable disease as determined by RECIST 1.1 and have progressed despite standard treatment or are intolerant to standard treatment, or for whom no standard treatment exists• Patients must have at least two sites of disease amenable to biopsy.
- Patient has an Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
Exclusion Criteria:
- Presence of symptomatic or uncontrolled central nervous system (CNS) metastases requiring local CNS-directed treatment.
- Patients diagnosed with hematological malignancies.
- Patients with prior stem cell transplants.
- Patients previously treated with TLR-7/8 agonist treatment.
- History of primary immunodeficiency
- Patients who discontinued prior anti-PD-1/PD-L1 therapy due to an anti-PD-1/PD-L1-related toxicity.
- Malignant disease, other than that being treated in this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LHC165 single agent
LHC165 intratumoral injection given alone
|
LHC165 intratumoral injection
|
Experimental: LHC165 in combination with PDR001
LHC165 intratumoral injection given with PDR001 infusion
|
LHC165 intratumoral injection
PDR001 infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Escalation: Incidence of Dose-limiting Toxicities (DLTs) in Cycle 1
Time Frame: day 28
|
Dose Limiting Toxicity Evaluation Period
|
day 28
|
Escalation and Expansion: Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs), including changes in laboratory parameters, vital signs, electrocardiograms (ECGs)
Time Frame: 24 months
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Objective Response Rate (ORR) per RECIST 1.1 and iRECIST
Time Frame: 24 months
|
24 months
|
Best Overall Response (BOR) per RECIST 1.1 and iRECIST
Time Frame: 24 months
|
24 months
|
Progression-Free Survival (PFS) per RECIST 1.1 and iRECIST
Time Frame: 24 months
|
24 months
|
Duration of Response (DOR) per RECIST 1.1 and iRECIST
Time Frame: 24 months
|
24 months
|
Disease Control Rate (DCR) per RECIST 1.1 and iRECIST
Time Frame: 24 months
|
24 months
|
Serum concentration profiles of LHC165 as a single agent: Cmax
Time Frame: 24 months
|
24 months
|
Serum concentration profiles of LHC165 in combination with PDR001 and derived PK parameters: Cmax
Time Frame: 24 months
|
24 months
|
Serum concentration profiles of PDR001 in combination with LHC165 and derived PK parameters: Cmax
Time Frame: 24 months
|
24 months
|
Serum concentration profiles of LHC165 as a single agent: AUC
Time Frame: 24 months
|
24 months
|
Serum concentration profiles of LHC165 in combination with PDR001 and derived PK parameters: AUC
Time Frame: 24 months
|
24 months
|
Serum concentration profiles of PDR001 in combination with LHC165 and derived PK parameters: AUC
Time Frame: 24 months
|
24 months
|
Serum concentration profiles of LHC165 as a single agent: Tmax
Time Frame: 24 months
|
24 months
|
Serum concentration profiles of LHC165 in combination with PDR001 and derived PK parameters: Tmax
Time Frame: 24 months
|
24 months
|
Serum concentration profiles of PDR001 in combination with LHC165 and derived PK parameters: Tmax
Time Frame: 24 months
|
24 months
|
Presence and titer of anti-PDR001 antibodies
Time Frame: 24 months
|
24 months
|
Change from baseline in tumor infiltrating lymphocytes in injected and distal tumor specimens
Time Frame: 24 months
|
24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Nehal Parikh, MD, Novartis Pharmaceuticals
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLHC165X2101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumors
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
National Cancer Institute (NCI)RecruitingSolid Tumor | Refractory Solid Tumors | Malignant Solid Tumors | Other Neoplasms Solid Tumors | Pediatric Solid TumorUnited States
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
-
Cancer Institute and Hospital, Chinese Academy...RecruitingRefractory Solid Tumors | Relapsed Solid TumorsChina
-
Genentech, Inc.RecruitingAdvanced Solid Tumors | Metastatic Solid TumorsCanada, Korea, Republic of, United States, Brazil, Australia, Argentina, Spain, New Zealand, Poland
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia